Edgewise Therapeutics Inc (EWTX)

[Whalatane]

Watch for a technical breakout as market anticipates the P1 HCM data
Mavacamten is I think the drug currently approved for HCM ( heart contractibility problems ) . The problem is it lowers ejection fraction ( the pump out movement ) to low for about 20% of the patients so it has a REMS rating limiting its use.
EWTX EDG-5506 works the same way but without the ejection fraction problem

Data due this Qt ( Q3 )

Kiwi